U.S. approves GSK, Xenoport drug for new use
 |
| A GlaxoSmithKline logo is seen outside one of its buildings in west London |
LONDON (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday. The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use. (Reporting by Ben Hirschler; editing by Kate Kelland) read more..
source:http://yhoo.it/KWnDD2
No comments:
Post a Comment